March 02, 2015 10:25 PM ET

Healthcare Providers and Services

Company Overview of KEW Group LLC

Company Overview

KEW Group LLC provides DNA based genomic testing and interpretation services with evidence-based diagnostic and treatment pathways to oncology practices. The company offers Therapeutic Pathways, a platform for personalized medicine, which provides information about current and emerging therapies, and is deployed in Web-based format for oncology practitioners and other healthcare workers; and KEW CancerPlexSM symbol, a gene testing panel to evaluate genetic changes in a patient's tumor to help oncologists manage treatment options. It also provides molecular genetic testing services, which determine whether a particular individual is at risk to develop certain types of cancers or examination o...

790 Memorial Drive

Suite 101

Cambridge, MA 02139

United States

Founded in 2009





Key Executives for KEW Group LLC

Chief Executive Officer, President and Director
Co-Founder and Chairman of the Board
Age: 71
Co-Founder and Director
Co-Founder, Director and Clinical Quality Board Chairman
Co-Founder and Board Observer
Compensation as of Fiscal Year 2014.

KEW Group LLC Key Developments

Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists

Cardinal Health Specialty Solutions and KEW Group Inc. announced an agreement for the two companies to make KEW's diagnostic services available to Specialty Solutions' community oncology customers. Cardinal Health Specialty Solutions customers will now have access to KEW's CancerPlex. CancerPlex: Simultaneously provides complete sequence coverage of more than 410 cancer genes; Simplifies and streamlines the test-ordering process by eliminating serial "hotspot" tests; Delivers a comprehensive report, including actionable data; Informs physicians of optimal treatment options using approved therapies and available clinical trials; and Supports clinical trial enrollment by providing oncologists with required molecular data.

KEW Group Inc. Appoints Scott Schell, MD, MBA, PhD as New President and CEO, Effective July 1, 2014

KEW Group Inc. announced the appointment of Scott Schell, MD, MBA, PhD, as KEW's new President and Chief Executive Officer. KEW is focused on revolutionizing cancer care by empowering oncologists to access and apply genomic insights to design optimal, individualized treatment approaches for patients. Dr. Schell, who will also become a member of KEW's Board of Directors, will commence his position at the company effective July 1, 2014. Most recently, Dr. Schell was instrumental in assisting the Cleveland Clinic in developing its strategy for population health management. Dr. M. Kathleen Behrens Wilsey, KEW's current CEO and a founder of the company, will remain a member of the Board of Directors of KEW Group, following Dr. Schell's transition to CEO.

KEW Group Secures Round of Financing

KEW Group Inc. secured private round of financing from Cardinal Health Inc. and The Bolyston Street Group. Leerink Partners LLC acted as placement agent for the transaction.

Similar Private Companies By Industry

Company Name Region
The Helixx, Inc. United States
Sentage Corporation United States
Therapeutic Research Center United States
Med-Quip Rental and Supplies, Inc. United States
Carolina Behavioral Services, Llc United States

Recent Private Companies Transactions

Private Placement
December 5, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KEW Group LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at